Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Breakthroughs, CEO Shakeup & 2025 Stock Outlook
Below we dive into a detailed analysis of RXRX – covering the latest developments, the company’s AI-powered business model, financials, key partnerships, expert commentary, technical trends, forecasts, and how Recursion compares to other AI-focused biotech players. Latest Developments and News (Early November 2025) Q3 2025 Earnings & Milestone: Recursion’s third-quarter 2025 report (released Nov 5) was a mixed bag. The company posted quarterly revenue of $5.2 million, a steep drop from $26.1 million in Q3 last year stocktitan.net. This was a significant miss versus Wall Street’s ~$17 million forecast, reflecting the lumpy nature of partnership payments (no big milestone was booked as revenue in